Cytokinetics(CYTK) - 2022 Q2 - Quarterly Report

PART I. FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations and comprehensive loss, stockholders' equity, and cash flows, along with detailed notes explaining the company's accounting policies, R&D arrangements, fair value measurements, balance sheet components, debt, equity, and commitments Condensed Consolidated Balance Sheets | ASSETS | June 30, 2022 (in thousands) | December 31, 2021 (in thousands) | | :---------------------------------- | :----------------------------- | :------------------------------- | | Cash and cash equivalents | $93,631 | $112,666 | | Short-term investments | $492,395 | $358,972 | | Accounts receivable | $1,973 | $51,819 | | Total current assets | $602,250 | $535,672 | | Total assets | $771,717 | $841,319 | | LIABILITIES AND STOCKHOLDERS' EQUITY | | | | Total current liabilities | $66,843 | $71,860 | | Term loan, net | $62,344 | $47,367 | | Convertible notes, net | $134,674 | $95,471 | | Liabilities related to revenue participation right purchase agreements, net | $282,266 | $179,072 | | Total liabilities | $660,303 | $597,456 | | Total stockholders' equity | $111,414 | $243,863 | - Total assets decreased from $841.3 million at December 31, 2021, to $771.7 million at June 30, 2022. Total liabilities increased from $597.5 million to $660.3 million, while total stockholders' equity decreased from $243.9 million to $111.4 million[11] Condensed Consolidated Statements of Operations and Comprehensive Loss | Metric (in thousands) | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :------------------------------------------------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development revenues | $968 | $2,843 | $2,116 | $9,391 | | Milestone revenues | $1,000 | — | $1,000 | — | | Realization of revenue participation right purchase agreement | $87,000 | — | $87,000 | — | | Total revenues | $88,968 | $2,843 | $90,116 | $9,391 | | Research and development expenses | $57,126 | $36,443 | $103,061 | $68,004 | | General and administrative expenses | $42,716 | $21,197 | $75,786 | $36,795 | | Total operating expenses | $99,842 | $57,640 | $178,847 | $104,799 | | Operating loss | $(10,874) | $(54,797) | $(88,731) | $(95,408) | | Net loss | $(19,820) | $(61,554) | $(109,265) | $(108,658) | | Net loss per share — basic and diluted | $(0.23) | $(0.86) | $(1.28) | $(1.52) | | Weighted-average number of shares used in computing net loss per share — basic and diluted | 85,731 | 71,754 | 85,366 | 71,476 | - Total revenues significantly increased to $88.968 million for the three months ended June 30, 2022, from $2.843 million in the prior year, primarily due to the realization of a revenue participation right purchase agreement. Net loss decreased to $(19.820) million from $(61.554) million in the same period[13] - For the six months ended June 30, 2022, total revenues were $90.116 million, up from $9.391 million in the prior year. Net loss remained relatively stable at $(109.265) million compared to $(108.658) million[13] Condensed Consolidated Statements of Stockholders' Equity | Stockholders' Equity Component (in thousands) | Balance, December 31, 2021 | Balance, June 30, 2022 | | :-------------------------------------------- | :------------------------- | :--------------------- | | Common Stock | $84 | $85 | | Additional Paid-In Capital | $1,452,268 | $1,422,127 | | Accumulated Other Comprehensive Loss | $(869) | $(4,494) | | Accumulated Deficit | $(1,207,620) | $(1,306,304) | | Total Stockholders' Equity | $243,863 | $111,414 | - Total stockholders' equity decreased from $243.863 million at December 31, 2021, to $111.414 million at June 30, 2022, primarily due to a net loss of $(109.265) million and a decrease in additional paid-in capital[15][13] - The adoption of ASU 2020-06 on January 1, 2022, resulted in a decrease of $49.476 million in additional paid-in capital and an increase of $10.581 million in accumulated deficit[27] Condensed Consolidated Statements of Cash Flows | Cash Flow Activity (in thousands) | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :-------------------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(117,286) | $(59,015) | | Net cash provided by investing activities | $989 | $13,605 | | Net cash provided by (used in) financing activities | $97,262 | $(421) | | Net decrease in cash and cash equivalents | $(19,035) | $(45,831) | | Cash and cash equivalents, end of period | $93,631 | $37,154 | - Net cash used in operating activities increased to $(117.286) million for the six months ended June 30, 2022, from $(59.015) million in the prior year, primarily due to ongoing R&D and G&A expenses[17][300] - Net cash provided by financing activities significantly increased to $97.262 million, driven by $149.6 million from the RP Aficamten RPA and RP Loan Agreement, partially offset by term loan repayments[17][302] Note 1 — Organization and Significant Accounting Policies - The Company is a late-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that modulate muscle function for serious diseases[19] - The Company has incurred an accumulated deficit of $1,306.3 million since inception and anticipates future operating losses and net cash outflows[20][319] Impact of ASU 2020-06 Adoption (as of January 1, 2022, in thousands): | Balance Sheet Account Description | Ending Balance of December 31, 2021 | ASU 2020-06 Adjustments | Beginning Balance of January 1, 2022 | | :-------------------------------- | :---------------------------------- | :---------------------- | :----------------------------------- | | Convertible notes, net | $95,471 | $38,895 | $134,366 | | Additional paid-in capital | $1,452,268 | $(49,476) | $1,402,792 | | Accumulated deficit | $(1,207,620) | $10,581 | $(1,197,039) | Note 2 — Net Loss Per Share | Instrument (in thousands) | June 30, 2022 | June 30, 2021 | | :------------------------ | :------------ | :------------ | | Options to purchase common stock | 11,057 | 9,463 | | Warrants to purchase common stock | 31 | 48 | | Restricted stock and performance units | 1,280 | 1,562 | | Shares issuable related to the ESPP | 11 | 10 | | Shares issuable upon conversion of convertible notes | 16,675 | 16,675 | | Total shares | 29,054 | 27,758 | - A total of 29.054 million and 27.758 million shares were excluded from diluted net loss per share computation for the six months ended June 30, 2022 and 2021, respectively, as their effect would have been antidilutive[29] Note 3 — Research and Development Arrangements - The Ji Xing OM License Agreement, part of the 2021 RTW Transactions, granted Ji Xing exclusive rights to develop and commercialize omecamtiv mecarbil in China and Taiwan, with a $50.0 million upfront payment received in January 2022 and potential milestones up to $330.0 million[32][34] - The Ji Xing Aficamten License Agreement, part of the 2020 RTW Transactions, provided a $25.0 million upfront payment and potential milestones up to $200.0 million for aficamten development and commercialization in China and Taiwan[41][45] - The Mavacamten Royalty Purchase Agreement resulted in $87.0 million revenue recognition in Q2 2022 due to the full extinguishment of the Mavacamten Royalty[50][277] | Revenue Source (in thousands) | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :---------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Astellas R&D revenue | $1,000 | $300 | $2,100 | $2,000 | | Amgen R&D revenue | — | $2,500 | — | $7,400 | Note 4 — Fair Value Measurements Fair Value of Financial Assets (June 30, 2022, in thousands): | Asset Type | Fair Value Hierarchy Level | Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value | | :------------------------------ | :------------------------- | :------------- | :--------------- | :---------------- | :--------- | | Money market funds | Level 1 | $69,939 | — | — | $69,939 | | U.S. Treasury securities | Level 1 | $223,239 | $9 | $(1,830) | $221,418 | | U.S. and non-U.S. government agency bonds | Level 2 | $27,751 | — | $(209) | $27,542 | | Commercial paper | Level 2 | $130,739 | $19 | $(420) | $130,338 | | U.S. and non-U.S. corporate obligations | Level 2 | $148,212 | — | $(2,062) | $146,150 | | Total | | $599,880 | $28 | $(4,521) | $595,387 | Available-for-Sale Securities (in thousands): | Category | June 30, 2022 | December 31, 2021 | | :----------------- | :------------ | :---------------- | | Cash equivalents | $92,324 | $115,937 | | Short-term investments | $492,395 | $358,972 | | Long-term investments | $10,668 | $152,050 | | Total | $595,387 | $626,959 | - Interest and other income, net, increased to $0.9 million for the three months ended June 30, 2022, from $0.2 million in the prior year, and to $1.3 million for the six months ended June 30, 2022, from $0.5 million in the prior year[71] Note 5 — Balance Sheet Components Accrued Liabilities (in thousands): | Category | June 30, 2022 | December 31, 2021 | | :------------------------- | :------------ | :---------------- | | Clinical and preclinical costs | $16,488 | $13,872 | | Compensation related | $12,522 | $14,930 | | Other accrued expenses | $7,692 | $5,568 | | Total accrued liabilities | $36,702 | $34,370 | - Total accrued liabilities increased to $36.702 million at June 30, 2022, from $34.370 million at December 31, 2021, primarily driven by an increase in clinical and preclinical costs[75] Note 6 — Agreements with Royalty Pharma - The 2022 RPI Transactions include a Development Funding Loan Agreement (RP Loan Agreement) for up to $300.0 million in term loans, with $50.0 million disbursed at closing and the remaining $250.0 million contingent on development milestones[82][306] - The RP Loan Agreement has an effective interest rate of 7.65% over a ten-year term, with aggregate repayment equal to 190% of the principal amount[83] - The Revenue Participation Right Purchase Agreement (RP Aficamten RPA) provides up to $150.0 million in consideration for rights to aficamten net sales, with $100.0 million received to date and $50.0 million contingent on nHCM trial initiation[88][311] - The RP Aficamten RPA involves a royalty of 4.5% on annual worldwide net sales up to $1 billion and 3.5% above $1 billion, with an imputed interest rate of approximately 11.7% as of June 30, 2022[89][91] Non-cash Interest Expense on Revenue Participation Right Purchase Agreements (in thousands): | Agreement | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :----------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | RP OM Liability | $4,429 | $2,871 | $8,707 | $5,666 | | RP Aficamten Liability | $2,574 | — | $4,860 | — | | Total | $7,003 | $2,871 | $13,567 | $5,666 | Note 7 — Debt - The Term Loan Agreement with Silicon Valley Bank and Oxford Finance LLC was terminated in January 2022, resulting in a $2.7 million loss on debt extinguishment for the six months ended June 30, 2022[108][288] - The 2026 Convertible Senior Notes have an aggregate principal amount of $138.0 million, bear 4.0% annual interest, and mature on November 15, 2026. The effective interest rate was 4.6% for the three and six months ended June 30, 2022[111][119] Interest Expense for 2026 Notes (in thousands): | Type of Interest Cost | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Contractual interest expense | $1,380 | $1,380 | $2,760 | $2,760 | | Amortization of debt discount | — | $1,445 | — | $2,816 | | Amortization of debt issuance costs | $164 | $14 | $309 | $28 | | Total interest expense recognized | $1,544 | $2,839 | $3,069 | $5,604 | - The fair value of the convertible notes was estimated at $655.8 million as of June 30, 2022, significantly exceeding its principal amount[120] Note 8 — Stockholders' Equity - The 2004 Equity Incentive Plan was amended in May 2022, increasing authorized shares by 6.0 million for general issuance and 1.6 million for inducement grants, totaling 10.3 million shares available for grant as of June 30, 2022[123] - The first tranche of Performance Stock Units (PSUs) met its performance target during the six months ended June 30, 2022, resulting in $0.4 million expense. The second tranche is unlikely to vest due to the FDA's extended PDUFA date for omecamtiv mecarbil[126] - Silicon Valley Bank exercised 16,901 warrants in May 2022, resulting in the issuance of 14,136 common shares via cashless settlement. As of June 30, 2022, 30,821 warrants remained outstanding[127] Note 9 — Commitments and Contingencies - The Oyster Point Lease for office and laboratory space has a remaining term of 11.3 years as of June 30, 2022, with total undiscounted future lease payments of $224.5 million[133] - A new Radnor Lease for office space commenced in Q3 2022, with total undiscounted lease payments of $2.9 million, but no right-of-use asset or lease liability was recognized as of June 30, 2022[135][136][137] - Finance leases for laboratory equipment, classified as such due to a bargain purchase option, have a weighted average remaining term of 4.5 years and total undiscounted future lease payments of $2.7 million[138][139][140][142] Rent Expense (in thousands): | Lease Type | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Operating and Finance Leases | $5,500 | $5,300 | $11,100 | $6,700 | Note 10 — Subsequent Events - On July 6, 2022, the Company issued $540.0 million aggregate principal amount of 3.50% Convertible Senior Notes due 2027 (2027 Notes), with net proceeds of approximately $523.3 million[143][145][147] - The 2027 Notes have an initial conversion rate of 19.5783 shares per $1,000 principal amount, equating to an initial conversion price of approximately $51.08 per share[146] - Concurrently with the 2027 Notes offering, the Company repurchased approximately $116.9 million aggregate principal amount of its 2026 Notes using $140.3 million in cash and issuing approximately 8.0 million common shares[147] Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section provides management's perspective on the company's financial condition and results of operations, including a discussion of forward-looking statements, business overview, research and development programs, critical accounting policies, detailed financial results, liquidity, and capital resources Forward-Looking Statements - The report contains forward-looking statements regarding future performance, capital requirements, clinical trial progress, regulatory approvals, and commercialization plans, which involve inherent risks and uncertainties[150][155] - Key risks include regulatory decisions (e.g., FDA approval for omecamtiv mecarbil), ability to meet funding conditions under Royalty Pharma agreements, patient enrollment, and the impact of the COVID-19 pandemic[155] Business - Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors[158] - The company's clinical-stage drug candidates include omecamtiv mecarbil (cardiac myosin activator for heart failure), CK-136 (cardiac troponin activator), reldesemtiv (fast skeletal muscle troponin activator for ALS), aficamten (cardiac myosin inhibitor for HCM), and CK-271 (second cardiac myosin inhibitor)[159] - The FDA accepted the NDA for omecamtiv mecarbil for HFrEF, and aficamten is in Phase 3 for symptomatic oHCM[160][163] Research and Development Programs - Research and development expenses increased by $20.7 million (YoY Q2) and $35.1 million (YoY H1) primarily due to increased clinical development activities for COURAGE-ALS, cardiac muscle inhibitor programs, and early research[27][171][279] Research and Development Expenses by Program (in thousands): | Program | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :---------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Cardiac muscle contractility | $27,664 | $26,175 | $53,151 | $42,412 | | Skeletal muscle contractility | $14,841 | $3,094 | $26,300 | $11,450 | | All other research programs | $14,621 | $7,174 | $23,610 | $14,142 | | Total | $57,126 | $36,443 | $103,061 | $68,004 | Cardiac Muscle Program - Omecamtiv mecarbil's NDA for HFrEF was accepted by the FDA, but the PDUFA target action date was extended to February 28, 2023, due to additional pharmacokinetic analyses[202] - GALACTIC-HF showed a statistically significant reduction in the primary composite endpoint (CV death or heart failure events) for omecamtiv mecarbil, with a potentially greater effect in patients with lower LVEF[184][187][190] - METEORIC-HF, a Phase 3 trial for omecamtiv mecarbil, did not meet its primary endpoint of improving exercise capacity (peak oxygen uptake)[201] - Aficamten received Breakthrough Therapy Designation for oHCM and showed positive topline results in REDWOOD-HCM Cohorts 1, 2, and 3, demonstrating significant reductions in LVOT-G and improvements in NYHA class[215][217][220][223][224] - SEQUOIA-HCM, a Phase 3 trial for aficamten in symptomatic oHCM, is open for enrollment, aiming for 270 patients[218][219] Skeletal Muscle Contractility Program - Reldesemtiv has Orphan Drug Designation for SMA and ALS in the U.S. and E.U[244] - COURAGE-ALS, a Phase 3 clinical trial of reldesemtiv in ALS patients, is open for enrollment, building on insights from FORTITUDE-ALS[257][258] - FORTITUDE-ALS did not achieve statistical significance for its primary endpoint but showed numerical effects favoring reldesemtiv, particularly in faster-progressing ALS patients[250][252][256] - The Astellas OSSA Agreement, focused on other skeletal sarcomere activators, was terminated effective November 1, 2021, with all licenses reverting to Cytokinetics[240][242] Beyond Muscle Contractility - The Company is leveraging its expertise in muscle biology to investigate new ways of modulating muscle function beyond contractility for other potential therapeutic applications[262] COVID-19 Business Update - The Company transitioned to a hybrid work model in March 2022 and continues to monitor and comply with guidance to protect employee and patient safety[264][265] - The COVID-19 pandemic continues to pose risks of significant and prolonged disruption to global financial markets, potentially affecting liquidity and business operations, including clinical trials[266][267] Critical Accounting Policies and Significant Estimates - The Company's financial statements are prepared in accordance with GAAP, requiring estimates and assumptions that affect reported amounts, which are evaluated on an ongoing basis[270] - Refer to Note 1 for a discussion of recently adopted and not yet adopted accounting pronouncements[271] Results of Operations Revenues (in thousands): | Revenue Type | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :---------------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development revenues | $968 | $2,843 | $2,116 | $9,391 | | Milestone revenues | $1,000 | — | $1,000 | — | | Realization of revenue participation right purchase agreement | $87,000 | — | $87,000 | — | | Total revenues | $88,968 | $2,843 | $90,116 | $9,391 | - Total revenues for the three and six months ended June 30, 2022, increased significantly by $86.1 million and $80.7 million, respectively, primarily due to the $87.0 million revenue recognition from the extinguishment of the Mavacamten Royalty[275][277] Operating Expenses (in thousands): | Expense Type | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :---------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $57,126 | $36,443 | $103,061 | $68,004 | | General and administrative | $42,716 | $21,197 | $75,786 | $36,795 | | Total operating expenses | $99,842 | $57,640 | $178,847 | $104,799 | - General and administrative expenses increased by $21.5 million (YoY Q2) and $39.0 million (YoY H1) due to higher outside service spend for commercial launch preparation of omecamtiv mecarbil, increased personnel costs, and facilities expense[285] - Interest expense decreased by $1.266 million (YoY Q2) and $2.508 million (YoY H1) due to the termination of the Term Loan Agreement, partially offset by interest from the RP Loan Agreement and 2026 Notes[287] - Non-cash interest expense on liabilities related to revenue participation right purchase agreements increased by $4.132 million (YoY Q2) and $7.901 million (YoY H1), primarily due to the RP Aficamten RPA[296] Liquidity and Capital Resources Financial Position (in thousands): | Category | June 30, 2022 | December 31, 2021 | | :---------------------------------------- | :------------ | :---------------- | | Total cash, cash equivalents and marketable securities | $596,694 | $623,688 | | Total borrowings | $197,018 | $142,838 | | Working capital | $535,407 | $463,812 | Cash Flow Summary (in thousands): | Activity | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :---------------------------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(117,286) | $(59,015) | | Net cash provided by investing activities | $989 | $13,605 | | Net cash provided by (used in) financing activities | $97,262 | $(421) | - Net cash provided by financing activities was $97.3 million, primarily from $149.6 million net proceeds from the RP Aficamten RPA and RP Loan Agreement, offset by term loan repayments[302] - The Company believes existing cash, cash equivalents, and investments will fund operations for at least the next 12 months, but significant additional funding will be required for future R&D and commercialization[22][320] Off-Balance Sheet Arrangements - The Company is not party to any off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on its financial condition, revenues, or expenses[321] Item 3. Quantitative and Qualitative Disclosures About Market Risk This section states that the company's exposure to market risk has not materially changed since the disclosures in its Annual Report on Form 10-K for the year ended December 31, 2021 - The Company's exposure to market risk has not materially changed since its Annual Report on Form 10-K for December 31, 2021[323] Item 4. Controls and Procedures This section details the evaluation of disclosure controls and procedures, confirming their effectiveness at a reasonable assurance level as of June 30, 2022, and states there were no material changes in internal control over financial reporting during the quarter - The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2022[324] - There were no changes in internal control over financial reporting during the quarter ended June 30, 2022, that materially affected, or are reasonably likely to materially affect, internal control over financial reporting[325] PART II. OTHER INFORMATION Item 1. Legal Proceedings This section states that there are no legal proceedings - The Company is not involved in any legal proceedings[327] Item 1A. Risk Factors This section outlines various risks that could materially and adversely affect the company's business, results of operations, financial condition, or investment in its securities. These risks span business operations, industry-specific challenges, and general financial and legal considerations - The Company has a history of significant losses and requires substantial additional capital to fund operations, with no guarantee of future profitability or financing availability on favorable terms[329][331][332] - The ability to obtain additional loan disbursements under the RP Loan Agreement and RP Aficamten RPA is subject to specific conditions and deadlines, which may not be met, especially given the extended PDUFA date for omecamtiv mecarbil[333][334] - Clinical trials are expensive, time-consuming, and prone to failure, with no guarantee that drug candidates like omecamtiv mecarbil, aficamten, or reldesemtiv will demonstrate the desired safety and efficacy for regulatory approval[360][361][382] - The Company relies heavily on CROs and CMOs for clinical trials and manufacturing, and any failure in their performance or inability to secure alternative partners could lead to significant delays and increased costs[405][407][411] - Intellectual property protection is crucial, but obtaining and enforcing patents is costly and uncertain, and the Company faces risks of infringement claims, challenges to ownership, and the potential for competitors to develop similar drugs[419][436][440] - The commercial success of approved products depends on market acceptance, third-party payor coverage, and favorable reimbursement, which are subject to significant uncertainty and potential cost-containment measures[490][493][495] Item 2. Unregistered Sales of Equity Securities and Use of Proceeds This section states that there were no unregistered sales of equity securities or use of proceeds to report - No unregistered sales of equity securities or use of proceeds to report[554] Item 3. Defaults Upon Senior Securities This section states that there were no defaults upon senior securities - No defaults upon senior securities to report[555] Item 4. Mine Safety Disclosures This section states that there are no mine safety disclosures - No mine safety disclosures to report[556] Item 5. Other Information This section states that there is no other information to report - No other information to report[557] Item 6. Exhibits This section lists the exhibits filed with the Quarterly Report on Form 10-Q, including certifications and XBRL documents - Exhibits include certifications from principal executive, financial, and accounting officers, as well as Inline XBRL documents[560][561][562][563][565][566] SIGNATURES - The report is signed by Robert I. Blum (President and Chief Executive Officer), Ching W. Jaw (Senior Vice President, Chief Financial Officer), and Robert C. Wong (Vice President, Chief Accounting Officer)[572]